Evidence map›Paper›PMID 33411866›Full record

ArticleChemical communications (Cambridge, England)2021

Fucosyltransferase-specific inhibition via next generation of fucose mimetics.

Kyle C Martin, Jacopo Tricomi, Francisco Corzana, Ana García-García, Laura Ceballos-Laita, Thomas Hicks, Serena Monaco, Jesus Angulo, Ramon Hurtado-Guerrero, Barbara Richichi and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chemical communications (Cambridge, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. E-selectin in vascular pathophysiology.Frontiers in immunology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Kyle C MartinDepartment of Translational Medicine, Translational Glycobiology Institute, Herbert Wertheim College of Medicine, Florida International University, Miami, FL 33199, USA. sackstein@fiu.edu and Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA and Program of Excellence in Glycoscience, Harvard Medical School, Boston, MA 02115, USA.
Jacopo TricomiDepartment of Chemistry 'Ugo Schiff', University of Florence, Via della Lastruccia 13, 50019 Sesto Fiorentino, FI, Italy. barbara.richichi@unifi.it.
Francisco CorzanaDepartamento de Química, Universidad de La Rioja, Centro de Investigación en Síntesis Química, 26006 Logroño, Spain.ORCID http://orcid.org/0000-0001-5597-8127
Ana García-GarcíaInstitute of Biocomputation and Physics of Complex Systems (BIFI), University of Zaragoza, Mariano Esquillor s/n, Campus Rio Ebro, Edificio I + D, Zaragoza, Spain.
Laura Ceballos-LaitaInstitute of Biocomputation and Physics of Complex Systems (BIFI), University of Zaragoza, Mariano Esquillor s/n, Campus Rio Ebro, Edificio I + D, Zaragoza, Spain.
Thomas HicksSchool of Pharmacy, University of East Anglia, Norwich Research Park, NR47TJ, Norwich, UK.
Serena MonacoSchool of Pharmacy, University of East Anglia, Norwich Research Park, NR47TJ, Norwich, UK.
Jesus AnguloSchool of Pharmacy, University of East Anglia, Norwich Research Park, NR47TJ, Norwich, UK and Departamento de Química Orgánica, Universidad de Sevilla, C/Prof. García González, 1, 41012 Sevilla, Spain and Instituto de Investigaciones Químicas (CSIC-US), Avda. Américo Vespucio, 49, 41092 Sevilla, Spain.
Ramon Hurtado-GuerreroInstitute of Biocomputation and Physics of Complex Systems (BIFI), University of Zaragoza, Mariano Esquillor s/n, Campus Rio Ebro, Edificio I + D, Zaragoza, Spain and Fundación ARAID, 50018, Zaragoza, Spain and Copenhagen Center for Glycomics, Department of Cellular and Molecular Medicine, School of Dentistry, University of Copenhagen, Copenhagen, Denmark and Laboratorio de Microscopías Avanzada (LMA), University of Zaragoza, Mariano Esquillor s/n, Campus Rio Ebro, Edificio I + D, Zaragoza, Spain.ORCID http://orcid.org/0000-0002-3122-9401
Barbara RichichiDepartment of Chemistry 'Ugo Schiff', University of Florence, Via della Lastruccia 13, 50019 Sesto Fiorentino, FI, Italy. barbara.richichi@unifi.it.ORCID http://orcid.org/0000-0001-7093-9513
Robert SacksteinDepartment of Translational Medicine, Translational Glycobiology Institute, Herbert Wertheim College of Medicine, Florida International University, Miami, FL 33199, USA. sackstein@fiu.edu and Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA and Program of Excellence in Glycoscience, Harvard Medical School, Boston, MA 02115, USA.ORCID http://orcid.org/0000-0003-1757-891X

Funding

Analysis of E-selectin Ligands of Human Acute Leukemia Cells and their Biology in LeukemogenesisU01CA225730 · NCI · FLORIDA INTERNATIONAL UNIVERSITY · PI MITSIADES, CONSTANTINE S., SACKSTEIN, ROBERT · 2019 to 2023
$3.0M
NCI NIH HHS U01 CA225730
6 · The paper itself

Abstract

The ability to custom-modify cell surface glycans holds great promise for treatment of a variety of diseases. We propose a glycomimetic of l-fucose that markedly inhibits the creation of sLe

Indexed as

Cell Line, TumorFucoseFucosyltransferasesGene Expression Regulation, EnzymologicHumansMesenchymal Stem CellsPrecursor Cell Lymphoblastic Leukemia-LymphomaFucoseFucosyltransferases

Identifiers

PMID33411866
PMCPMC12817676

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.